cancer vaccines

Moderna's cancer breakthrough has not earned a durable rerating

The melanoma Phase 3 headline is meaningful, but it has not supplied the hazard ratios, survival detail, or commercial proof needed for a lasting valuation reset. With revenue down 39.2% and a -141.4% net margin, MRNA still trades like a de-risked growth story while the earnings engine remains broken.